NUKEMED, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.spectronrx.com
Safety and Targeting of Anti-hk2 Antibody in mCRPC
Early Phase 1
Terminated
- Conditions
- Castration-Resistant Prostatic CancerMetastatic Disease
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- SpectronRX
- Target Recruit Count
- 27
- Registration Number
- NCT04116164
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath